3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
14
Neoplasms
10
Thoracic Neoplasms
3
Carcinoma
3
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
NSCLC
2
Meningeal Carcinomatosis
2
Lung Diseases
2
Colorectal Neoplasms
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma
2
Solid Tumor, Adult
1
Renal Insufficiency
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Noonan Syndrome
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma, Malignant
1
Lung Cancer Metastatic
1
Lethal Congenital Contracture Syndrome 2
1
Hemangioendothelioma, Epithelioid
1
Head and Neck Neoplasms
1
Interventions
tremelimumab
3
durvalumab
3
Ipilimumab
3
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Vaccination
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Monophenol Monooxygenase
1
Melphalan
1
Docetaxel
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Diabetes Mellitus, Insulin-Dependent, 12
×
osimertinib
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled